WANBURY · Wanbury Ltd · Biotechnology & Drugs
WANBURY · Wanbury Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
44.5% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹166 Cr
Revenue YoY
PAT YoY
-76.0%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.6
P/S (TTM)
1.3
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| WANBURY (this stock) | 17.3 | 5.6 | +8.6% | +38.7% | 1.55 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-10-06 | WANBURY | 0 | 0 | STRONG | BULK |
| 2026-08-12 | WANBURY | 241998 | 1 | STRONG | BULK |
| 2026-08-11 | WANBURY | 217468 | 1 | MEDIUM | BULK |
| 2026-07-14 | WANBURY | 851447 | 4 | WEAK | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: The investor presentation from Wanbury Limited, dated July 1, 2026, provided an overview of the company's audited financial results for the quarter and year ended March 31, 2026. Management reported a successful turnaround to growth momentum, highlighting global market leadership in key products such as Metformin and Sertraline. The presentation detailed a significant operational and financial turnaround over the past three years, with a focus on building new growth drivers in the API business. Management noted a de-risked balance sheet with a moderate leverage ratio of approximately 2X Debt/EBITDA. The company achieved its highest-ever operational EBITDA of ₹108 crore in FY26 and reported an 8% year-on-year revenue growth to ₹650 crore. The formulations business reached break-even profitability in FY26, supported by new product launches and an improved go-to-market strategy. The presentation emphasized the company's commitment to operational efficiencies and regulatory compliance.
Management emphasized growth and operational improvements throughout the presentation.
Sourced from an exchange-filed presentation, dated 01 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Wanbury Limited, dated February 9, 2026, detailed the company's financial performance for the quarter and nine months ended December 31, 2025. Management reported a 22% year-over-year revenue growth in Q3FY26, with total revenues for 9MFY26 increasing by 14%. EBITDA saw a significant rise of 91% year-over-year in Q3 and 65% in the nine-month period, attributed to improved operational efficiency and reduced finance costs. The API business achieved a milestone with the commissioning of a new production block for a high-potent anaesthetic product, while the Formulations segment also reported positive EBITDA contributions. Management highlighted a focus on profitability and operational execution, with plans for multiple new product launches in the upcoming financial year. The presentation included insights into the company's strategic direction, operational turnaround, and financial health, emphasizing a robust balance sheet and established global regulatory approvals.
Management emphasized strong operational performance and growth momentum.
Sourced from an exchange-filed presentation, dated 09 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedWanbury Limited's 2025-2026 annual report highlights its focus on expanding its pharmaceutical API business through capacity enhancement and new molecule commercialization. The report mentions continued investment in R&D for new APIs and regulatory filings to support its regulated-market strategy. The company also emphasizes sustainability initiatives, including electronic distribution of reports to reduce environmental impact. Additionally, the report outlines plans for strategic growth in formulations by shifting towards specialty and chronic-therapy segments while strengthening its Coriminic brand.
- Expansion of API manufacturing capacity through de-bottlenecking and brownfield projects to support volume growth.
- Strategic focus on commercializing new molecules, with management targeting approximately four launches per year starting FY 2026-27.
- Investment in in-house R&D for new API development, including molecules like Anaesthetic API, Rivaroxaban, and Sitagliptin.
- Shift in formulations business towards specialty and chronic-therapy segments with brand-building initiatives for Coriminic and C-RED.
- Adoption of electronic report distribution as part of sustainability efforts to minimize environmental impact.
Key takeaway: Wanbury Limited is prioritizing capacity expansion, new molecule commercialization, and R&D investment to drive growth in its pharmaceutical API business while adapting to regulatory and market dynamics.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceEarlier (1-3 years ago)
The auditor states that there is a material uncertainty about the company's ability to continue as a going concern, which may cast significant doubt on its financial viability.
Regulatory Action
2 occurrencesEarlier (1-3 years ago)
The company was levied penalties by NSE and BSE for non-compliance with Listing Regulations, including Rs.6,41,920/- paid to NSE for the quarter ended 30 September 2024 and Rs.6,46,640/- paid to BSE and NSE for the quarter ended 31 December 2024.
The company paid penalties of Rs. 2,24,000 to BSE and NSE for non-compliance with Regulation 33 of Listing Regulations.
Routine disclosures
Contingent Liability
2 occurrencesEarlier (1-3 years ago)
State Bank of India, London, filed legal proceedings in 2017 demanding repayment of ₹ 3,436.03 Lakhs plus interest from the company under a guarantee and loan agreement. A compromise settlement in 2018 approved repayment at 20%.
The company has disputed demands from Sales Tax, Service Tax, Income Tax, GST, and NPPA authorities, with amounts paid under protest, and no provision has been made for these contingencies.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The company proposes to appoint Ms. Anisha Rayana, daughter of a Whole-time Director, as a Management Trainee. The appointment requires shareholder approval as it exceeds the ₹ 2,50,000 monthly remuneration threshold under Section 188(1)(f) of the Companies Act, 2013.
The company had transactions with M/s. Wanbury Infotech Private Limited, a related party, which were in the normal course of business.
Statutory dues in dispute
2 occurrencesEarlier (1-3 years ago)
The company has statutory dues pending before authorities, including Income Tax, Goods and Service Tax, Customs Duty, and Cess, with disputes pending in various forums.
The company has pending disputes for statutory dues under various acts, including Central Sales Tax and Service Tax, with amounts ranging from FY 1997-98 to FY 2010-12, pending before Andhra Pradesh High Court and Central, Excise and Service Tax Appellate Tribunal, Mumbai.
Management & Board Governance
1 occurrenceEarlier (1-3 years ago)
The company's board of directors had fewer than 6 members due to the completion of terms of two non-executive independent directors, and the Nomination and Remuneration Committee had insufficient members after a director's resignation, though compliance was achieved by January 8, 2025, with new appointments.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
4.88% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18). Change vs the previous disclosure: decreasing.